The Mason, Ohio-based company posted losses of $3.4 million, or 9¢ per share, on sales of $52.9 million for the three months ended December 31, seeing losses grow 32.9% while sales grew 14.8% compared with the same period during the previous year.
Losses per share were ahead of the 17¢ loss-per-share consensus on Wall Street.
For the full year, AtriCure posted losses of $21.1 million, or 62¢ per share, on sales of $201.6 million, seeing losses shrink 21.4% while sales grew 15.4% compared with the previous fiscal year.
“We are pleased with our fourth quarter performance, capping a year of strong, consistent revenue growth. We are successfully building scalable infrastructure across the entire organization, positioning the company to efficiently expand and grow over the next decade. We remain committed to improving the lives of Afib patients globally, and we have created a strong foundation and culture based on this mission,” prez & CEO Mike Carrel said in a press release.
AtriCure released guidance for 2019, expecting to see sales of between $220 million and $228 million with a net loss per share of between 68¢ and 78¢.
Shares in AtriCure are down approximately 0.5% today, at $31.79 as of 11:02 a.m. EST.
Last month, AtriCure launched its CryoIce CryoSphere probe in the U.S.